Barclays’s Aegerion Pharmaceuticals AEGR Stock Holding History

Barclays’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-41,000	Closed	-$410K	–	6710
2015 Q4	$410K	Buy	+41,000	New	+$494K	﹤0.01%	3359
2014 Q2	–	Sell	-177,700	Closed	-$8.17M	–	7944
2014 Q1	$8.17M	Buy	+177,700	New	+$10.4M	0.01%	1301
2013 Q4	–	Sell	-315,100	Closed	-$26.8M	–	7827
2013 Q3	$26.8M	Buy	+315,100	New	+$26.7M	0.03%	525

Barclays's AEGR Position: Q4 2016 in Review

Barclays sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 1,598 shares — an estimated $5K sold.

Barclays first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $18.4M in Q4 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Barclays reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Barclays sold 1,598 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $5K.
Barclays first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Barclays's Aegerion Pharmaceuticals position peaked at $18.4M in Q4 2013.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Barclays's 13F filing for Q4 2016, filed 14 Feb 2017.